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Abstract The cost of transportation for monthly clinic
visits has been identiﬁed as a potential barrier to antiret-
roviral (ARV) adherence in sub-Saharan Africa and
elsewhere, although there is limited data on this issue. We
conducted open-ended interviews with 41 individuals liv-
ing with HIV/AIDS and attending a clinic in Mbarara,
Uganda, to understand structural barriers to ARV adher-
ence and clinical care. Almost all respondents cited the
need to locate funds for the monthly clinic visit as a con-
stant source of stress and anxiety, and lack of money for
transportation was a key factor in cases of missed doses
and missed medical appointments. Participants struggled
with competing demands between transport costs and other
necessities such as food, housing and school fees. Our
ﬁndings suggest that transportation costs can compromise
both ARV adherence and access to care. Interventions that
address this barrier will be important to ensure the success
of ARV programs in sub-Saharan Africa.
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Introduction
Antiretroviral (ARV) adherence is a key determinant of
clinical outcomes, including viral load suppression, emer-
gence of drug resistance, and progression to AIDS and
death (Bangsberg et al. 2000, 2001, 2006; Wood et al.
2003). In the past decade, there has been a marked
expansion in the distribution of highly active antiretroviral
therapy (HAART) in resource-constrained countries, as a
result of international initiatives such as the US govern-
ment’s President’s Emergency Plan for AIDS Relief
(PEPFAR) and the Global Fund to Fight AIDS, Tubercu-
losis and Malaria. Studies from low-resource settings have
reported adherence rates that are equivalent to or higher
than those in resource-rich countries (Hardon et al. 2007;
Laurent et al. 2002; Mills et al. 2006; Orrell et al. 2003;
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adherence have been found despite structural barriers that
can exact a signiﬁcant economic and emotional toll on
patients with HIV and their families (Byakika-Tusiime
et al. 2005; Crane et al. 2006; Hardon et al. 2007; Mills
et al. 2006; Weiser et al. 2003). Yet, some experts have
cautioned that high levels of adherence may not be sus-
tainable over the long term (Gill et al. 2005).
In earlier studies in resource-limited countries, the cost
of antiretrovirals (ARVs) was found to be among the most
signiﬁcant structural barriers to adherence (Crane et al.
2006; Ivers et al. 2005; Kumarasamy et al. 2005; Mshana
et al. 2006; Safren et al. 2005; Weiser et al. 2003). For-
tunately, many programs now provide ARVs free of
charge, eliminating the need to pay for them as a source of
concern and anxiety for program participants. However,
the provision of free antiretroviral therapy has not elimi-
nated ﬁnancial barriers to adherence.
One such barrier is the cost of transportation to clinic to
pick up monthly reﬁlls. The cost of transportation relative to
incomecanbesubstantial,especiallyforthoselivinginrural
areas, and must compete with other essential expenses, such
as for food, shelter or education. Several studies have found
transportation costs to be a potential barrier to sustained
antiretroviral treatment (Hardon et al. 2007; Mills et al.
2006; Mshana et al. 2006; Mukherjee et al. 2006; Weiser
et al. 2003). However, these studies have not examined the
mechanisms through which transportation costs may inter-
fere with adherence and treatment retention, nor the
strategies that patients use to cope with the added ﬁnancial
and emotional burdens posed by transportation costs.
Qualitative research is an important source of informa-
tion about patient attitudes, experiences and feelings related
to adherence and the barriers that impact it (Gill et al. 2005).
We conducted semi-structured qualitative interviews in a
population of HIV-positive patients receiving antiretroviral
therapy in rural Uganda to understand how transportation
costs are perceived, experienced and addressed by HIV-
positive patients in medical care in a resource-constrained
setting.
Methods
In-depth interviews exploring issues related to adherence,
including the impact of transportation costs, were con-
ducted in August and September 2007 with 41 people
living with HIV/AIDS attending the Immune Suppression
(ISS) Clinic at the Mbarara University of Science and
Technology in Mbarara, Uganda. Mbarara is a small urban
trading center in southwestern Uganda. The ISS Clinic
serves as a regional distribution point for free ARVs and
draws a largely rural population. A smaller number of
patients are from Mbarara town or surrounding urban
centers.
Participants were recruited from among patients who
arrived at the clinic each morning to pick up their monthly
supply of ARVs or receive treatment. Patients were
selected through purposive sampling, a common qualitative
research strategy that involves choosing subjects based on
speciﬁc characteristics and attributes in order to ensure that
a range of perspectives is represented (Creswell 1998). Our
goal was to include signiﬁcant numbers of both women and
men, people from both rural and urban areas, and indi-
viduals in different phases of HIV disease. In addition, we
wanted to interview at least ten participants not yet on
HAART to explore their perspective on barriers to HAART
initiation. Since clinic staff knew the personal situations of
many of the patients, we requested that they seek out
potential participants from all of our categories of interest.
Participants received a voucher for lunch and the cost of
transportation back home to compensate them for their
time.
We conducted semi-structured interviews with study
participants. Thirty-ﬁve interviews were conducted by one
of the study investigators in conjunction with a trained
interviewer-interpreter in English and Runyankole, the
main regional language. Six interviews were conducted
completely in Runyankole by the trained interviewer alone.
Interviews lasted from 30 min to 2 h, and most took place
in a private room at the clinic. Interviews were conducted
using a guide that included a number of open-ended
questions and probes. Domains of inquiry for the inter-
views included barriers to HAART initiation and
adherence; competing demands between food, transporta-
tion costs, school fees, and other family expenses; medical
history; sexual risk-taking, and family food security and
eating patterns. We probed in detail about episodes of
missed or delayed antiretroviral doses, including the exact
circumstances surrounding the missed or delayed doses, the
patient’s feelings about the missed or delayed doses, and
the speciﬁc impact of transportation costs, food shortages,
and any other structural factors on ARV adherence when
volunteered by the participant.
All interviews were digitally recorded, translated from
Runyankole into English, and transcribed. Through an
initial review of the interviews, two of the study investi-
gators identiﬁed repeated observations in the data and
synthesized those into several major themes, each with a
number of subordinate themes. The investigators then
coded the interviews for these themes. Coding discrepan-
cies were discussed and resolved. In the present paper we
focus on transportation costs as a barrier to adherence and
use selected quotations to illustrate key points.
All study procedures received approval from both the
University of California, San Francisco, Committee on
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and Technology (MUST) Institutional Review Board.
Results
Forty-one participants—25 women and 16 men—were
interviewed for the study. They ranged in age from 24 to 57,
with a mean age of 37 for the women and 40 for the men.
Twenty-three of the participants were from rural areas, six
from urban areas, and 12 from peri-urban areas. Gardening
and farming were the most frequent occupations. Thirty
reported being on a HAART regimen for a period of time
ranging from one month to several years, although many
could not remember speciﬁcally when they started. Eleven
had not yet initiated HAART. Of those already on HAART,
13 participants acknowledged having missed one or more
doses of their ARVs since they started treatment. The
remainder said they had never missed a dose.
All participants were asked about how they traveled to
the clinic and how they found the money to cover trans-
portation costs. None reported walking to the clinic on a
routine basis. For ﬁve participants who lived within a few
miles, the clinic was a short ride on a bus or motor-scooter-
taxi, known as a boda–boda, with a round-trip fare usually
costing from $0.60 to $1.50 (about 1,000–2,500 Ugandan
shillings at the exchange rate during September 2007,
which was approximately $1–1,700 Ugandan shillings).
The other 36 participants lived farther from the clinic—
some up to several hours away by car or public transpor-
tation—and generally reported that the round-trip fare for
their monthly clinic visits was between about $1.75 and
$11.75. The higher cost represents almost half of the mean
per capita annual income in Uganda of $300, or $25 a
month (Uganda Country Proﬁle 2008).
Non-Adherence
The difﬁculty that transportation costs imposed on efforts
to adhere to a regular medication schedule was a key theme
that emerged irrespective of whether participants were able
to maintain their ARV regimens. Even for many who
reported strict compliance, transportation costs caused
signiﬁcant concerns and anxieties about whether or not
they would be able to successfully adhere in the following
month and into the future. Individuals who missed doses
cited problems ﬁnding transportation money as a key rea-
son for not being able to maintain their regimen, explaining
that they were unable to afford to travel to the clinic before
their supply of ARVs ran out.
A 32-year-old woman with four children said she
sometimes did not have the money for transport because
her husband, a trader, was often away on business.
‘‘Sometimes it is time to come for my reﬁll and I do not
have transport, so I cannot come,’’ she said. ‘‘The time it
happened, I sent my papers with someone, but they refused
to give him my reﬁll because they said I have to get it
myself.’’
A widow who sold mats and baskets she wove from
palm leaves said she once missed almost a month of ARVs
because of a shortage of funds:
You may fail to get the 10,000 [shillings] to bring you
here, and you end up getting maybe 1000, 2000, and
when you get that little, you divert it to food and
some medicine, and then wait until you get enough
money to bring you to Mbarara.
Some patients cited loss of income associated with HIV-
related illness as one mechanism leading to difﬁculty with
transportation costs. A 45-year-old father of ﬁve, who had
missed weeks of medication because he could not afford
transportation, blamed his difﬁculties on his inability to
work:
Usually my transport is in such a way that by the time
I get to the next appointment, I don’t have money for
it. And ever since I fell sick, my strength has been
going down and I am very weak, and I don’t have
energy to go to the plantation and cut down matoke [a
green plantain cultivated as a staple] for sale, or even
plant some beans for sale.’’
Another participant, a 38-year-old woman with seven
children, missed a month when she could not work, and the
family’s retail business also failed:
It was about the time I fell sick, and I didn’t have
strength to do some gardening, and it was around the
same time that the store collapsed, so there was no
money for transport…I was feeling very weak and I
was sleeping most of the time, and I would feel that
since I was missing medicine that I was supposed to
be taking, I would be dying any minute.
Even for those not yet taking ARVs, anxiety over the
cost of transportation caused them to wonder if they would
be able to adhere to their medication regimens once they
started. One woman preparing to start HAART said that
lack of funds had already caused her to miss clinic
appointments twice to see the doctor and pick up other
medications to prevent opportunistic infections. She said
she doubted that she would be able to afford monthly visits
if she were to start taking ARVs:
I wouldn’t have to worry so much about it, if I didn’t
have to think about the word ‘transport.’ I have a low
income. It’s going to be a difﬁcult thing, because
780 AIDS Behav (2010) 14:778–784
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staying in the rural village areas…I think it’s very
important to come here for the medicine, but then I
can’t refuse to buy books for my child so as to spare
transport to come here.
Difﬁcult Choices
Another major theme that appeared repeatedly across the
sample was that transportation costs forced participants
into having to make serious sacriﬁces in other essential
arenas. Despite the above-cited examples of non-adher-
ence, patients generally expressed their determination to
sustain treatment and reported that saving money for
transportation came above all else. One woman noted that
she and her husband, who was also infected, ‘‘sacriﬁce as
much as we can’’ to obtain the money for the round-trip
fare. ‘‘It’s only natural that we’d want to be alive and
living,’’ she added. ‘‘So what we do, before our medicine
gets ﬁnished, we do everything to make sure that there is
money for transport to bring us.’’
For almost all the respondents, ‘‘doing everything’’ to
secure transportation money meant spending less on other
needs. Many were deeply aware that their determination to
keep their medication appointments meant less money for
family essentials. One woman, a 34-year-old living with
her parents since separating from her husband three years
before, said she spent the money on transportation to get
her medication even when she had no food: ‘‘It happens
sometimes that I regret that I’m spending 500 shillings on a
boda–boda when I know that back home there is nothing to
eat. But then I do not have a choice.’’
A 44-year-old woman with four children, whose hus-
band died in 2001, acknowledged that she also felt
conﬂicted when she hired a boda–boda to bring her to
clinic. ‘‘I feel bad when I have to spend that money on
transport when I could have spent it on something
else…[but] I must come to pick up my medicine,’’ she said.
‘‘I can give up any other thing, but do not think I can give
up my medicine. It would take ﬁrst priority if I had to
choose between it and something else.’’ An unmarried 26-
year-old, who had been deserted by the father of her two
children, said: ‘‘Sometimes I have to do without maybe
salt, parafﬁn, kerosene, so that I can get the transport to
come here.’’
Even when participants managed to pay for transporta-
tion to their monthly clinic visit, the constant search for
money caused them a signiﬁcant amount of psychological
and emotional distress. ‘‘It’s my most, most worrying
problem, because every time I have to come, I usually do
not have transport, and it keeps me awake most of the
time,’’ said a 35-year-old widow with ﬁve children.
In particular, respondents discussed how difﬁcult it was
for them to balance their need for transportation against the
need to pay for food, school fees, and other necessities for
themselves and their families. They felt forced into having
to make difﬁcult choices between unattractive alternatives.
A mother of ﬁve, long separated from her husband, said her
awareness of what she and her family must sacriﬁce because
of her illness troubled her:
Yes, I think about that 20,000 [to pay for transpor-
tation], I think about the fact that if I didn’t have HIV,
I wouldn’t have to spend that money to come here for
treatment. I imagine all the other things it could have
been used for, and I don’t feel peace in my heart. I
could hire people to do the digging, pay for school
fees, buy more food. There’s no way I can even think
of eating chicken, ﬁsh and meat as often as I’d like
when I have to get money for transport to this place.
A 46-year-old man, a farmer with ﬁve children who
lived far from the Mbarara clinic, said that his fear about
not being able to ﬁnd transportation money every month
took a deﬁnite psychological toll. ‘‘Transport…almost like
drains me because sometimes we look at our situation and
there is almost no way out,’’ he said. ‘‘And in the near
future we might sell our shirts so as to be able to raise the
transport, since I know that without the medicine I cannot
exist, and yet I do not have the money to come to pick the
medicine up.’’
Coping Strategies
In order to save or ﬁnd the money for transportation, par-
ticipants either devised strategies for saving money despite
the deprivations they faced, or else borrowed money to
make ends meet. Some reported that they tried to put aside
some portion of whatever they managed to earn, even when
they or members of their family did not always have what
they needed. ‘‘I do work for other people and they pay
about 1,000 shillings,’’ said a 46-year-old father of ﬁve,
who needed 20 times that amount for one round-trip fare to
the clinic. ‘‘Half of the payment I use to look for food, and
the other half I keep. And I do that till the end of the month.
The money I keep is my transport.’’
When he did not have enough money, said the man, he
entered into an agreement with another local HIV-positive
man on HAART:
We combine the money collected such that every
month, only one of us can come to pick up the
medicine for both of us. In case one of us does not
have enough contribution towards transport, the one
coming to pick up the medicine takes credit while the
AIDS Behav (2010) 14:778–784 781
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cover the other one’s debt.
Another man, a 32-year-old whose wife and youngest
child were also infected, said he decided to remove his
children from private school to help him save the funds he
needed every month for the round-trip fare. He earned
money by selling produce from the family garden at a stall
in the marketplace:
I plan that as the month begins I have to ﬁrst earn
16,000 shillings for transport to the clinic to pick up
the medicine…I always have a store, and every time I
am selling, I am always planning for the month that’s
coming. I always make sure to save enough…You
cannot really be able to determine how much money
you will earn in a day and therefore how much will be
saved per day, but I always try to save 500 shillings
per day when the circumstances allow it.
Many respondents talked about borrowing transportation
money from family, friends, and social clubs or organiza-
tions as one way they managed to access funds for clinic
visits and other expenses. And those with assets reported
that they sometimes had to sell their assets in order to
afford transport costs, among other expenses. A 44-year-
old widower with four children explained: ‘‘I just sold a
piece of my plantation to my brother and was using that
money for transport here, and to pay for credit, and take
care of some home basics.’’
Discussion
Most studies among people living with HIV/AIDS on
antiretroviral therapy in sub-Saharan Africa have found
high rates of adherence (Hardon et al. 2007; Laurent et al.
2002; Mills et al. 2006; Orrell et al. 2003; Oyugi et al.
2004; Rosen et al. 2007; Weiser et al. 2003). Yet the
presence of many structural and ﬁnancial barriers to
adherence, which have been documented in both qualita-
tive and quantitative research, raises questions about
whether and for how long such high rates of adherence are
sustainable (Gill et al. 2005). The present study’s ﬁndings
conﬁrm that even when patients have a high level of
commitment to medication adherence, economic factors—
in particular, the high cost of transportation for monthly
clinic visits—are an important challenge to sustained
treatment success. While other studies have cited trans-
portation costs as one of the many structural barriers to
treatment retention and adherence, this is the ﬁrst published
qualitative study to our knowledge to explore in depth the
relationship between transportation costs and adherence in
a low-resource setting.
The barriers imposed by transportation are multi-faceted
(Ware et al. 2006). They include the direct expense of
gasoline or transportation fares as well as the opportunity
costs of spending hours, a whole day, or even more than
one day traveling to and from clinic to pick up medication.
In Uganda and other countries of sub-Saharan Africa, many
people live in rural areas and must travel at signiﬁcant cost
in money and time to reach the hospitals or HIV clinics that
distribute the ARVs free of charge. With the current vol-
atility in oil prices, transportation costs can also change
quickly, making it even harder to plan for upcoming
clinic visits. One recent study found that having to travel
long distances to pick up medication did not negatively
impact adherence (Carlucci et al. 2008). However, the
sample was drawn through a drug distribution program
with prescreening requirements that selected for highly
motivated patients, so whether the ﬁndings can be extrap-
olated to other populations remains unclear.
For participants in the current study, the need to locate
transportation funds was a constant challenge. They
described how they must weigh these transportation costs,
which can absorb a signiﬁcant chunk of their monthly
income, against other necessities, either for themselves or
their families. They confront a difﬁcult dilemma: whether
to spend money on obtaining the ARVs that help keep them
alive or on meeting the high ﬁnancial burdens of food,
housing, and school. The starkness of the choice highlights
the possibility that adhering to ARV medications can
compromise other aspects of health and well-being, if
nutrition, shelter, and education are being sacriﬁced in
order to sustain treatment. Certain coping strategies adop-
ted by patients may also have unintended health
consequences. For example, when patients pick up ARVs
for each other to save money on transportation costs, the
absent patient does not receive the beneﬁts of health
counseling and other clinic services that month.
Difﬁculties with transportation costs can not only
impede day-to-day adherence to antiretroviral therapy but
can also impact retention in care and lead to signiﬁcant
loss-to-follow-up (Rosen et al. 2007). Rosen has noted that
most studies of HAART use in sub-Saharan Africa have
not included patients lost-to-follow-up when determining
adherence rates, even though similar barriers, such as high
transportation costs, can lead to both interruptions in
treatment access and loss-to-follow-up.
Our ﬁndings support the proposition that the concept of
access to medication—or lack thereof—may be a more
fruitful approach to the issue of missed doses than a strict
focus on adherence (Bangsberg et al. 2006; Crane et al.
2006). Researchers have discussed the importance of
disaggregating two distinct—but often conﬂated—con-
cepts: failure to adhere, and lack of access. When structural
and ﬁnancial barriers make it difﬁcult or impossible for
782 AIDS Behav (2010) 14:778–784
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interpreted as evidence of poor adherence skills or lack of
motivation. In fact, such barriers are prime examples of
what Farmer and others have referred to as ‘‘structural
violence,’’ in which societies constrain individual agency
and action through the unequal distribution of power,
wealth and other resources (Farmer 1999).
The distinction between failure to adhere and lack of
access is important because each construct implies a dif-
ferent approach to intervention. As researchers have noted,
interventions focused on increasing information, motiva-
tion and behavioral skills can help address causes of non-
adherence within an individual’s control, but reducing
structural and economic barriers is essential to prevent non-
adherence that arises from lack of access to ARVs.
Interventions for reducing the impact of transportation
on sustaining complicated medication regimens are already
being explored by community-based groups in sub-Saharan
African and elsewhere (Behforouz et al. 2004; Koenig et al.
2004; Weidle et al. 2006). Such interventions include sub-
sidizing travel costs and delivering drugs directly to the
community through home-based care models, neighbor-
hood drug dispensaries and local hospitals and primary care
clinics. Other possible interventions include expanding the
use of mobile clinics, strengthening support groups for
people living with HIV/AIDS, and augmenting adherence
counseling sessions with a discussion of transportation costs
as a potential barrier to clinic attendance. Future research
should focus on the effectiveness of these and other inter-
ventions to decrease barriers related to transportation costs.
There are several limitations to our study. We did
not interview individuals who were lost-to-follow-up, for
whom transportation might have been an even greater bar-
rier. Most of the interviews were conducted through an
interpreter by a non-Ugandan investigator, although similar
themes emerged from interviews conducted by a trained
investigator-interpreter from Mbarara. Despite these limi-
tations, the extensive dialogue facilitated by the qualitative
interview strategy revealed nuances of patients’ percep-
tions, attitudes, and behavior that are hard to obtain from
strictly quantitative methodologies but that are nonetheless
important to consider in future development of ARV dis-
tribution programs in Uganda and elsewhere in sub-Saharan
Africa.
In conclusion, our study was to our knowledge the ﬁrst
qualitative report to focus in depth on transportation costs
as an important barrier to adherence and treatment reten-
tion in sub-Saharan Africa. Our ﬁndings suggest that: (1)
patients have a high level of commitment to medication
adherence; (2) the high cost of transportation for monthly
clinic visits is a serious concern for many individuals and
can compromise both ARV adherence and access to care;
and (3) transportation costs compete with other essential
personal and family needs when resources are scarce.
Creative interventions to address the barriers posed by
transportation costs are likely to be necessary to ensure
sustained ARV adherence over the long term.
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